Mario Alberto Accardi Sells 8,000 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Mario Alberto Accardi sold 8,000 shares of the firm’s stock in a transaction on Monday, October 27th. The stock was sold at an average price of $25.00, for a total value of $200,000.00. Following the sale, the insider owned 194,394 shares in the company, valued at $4,859,850. This trade represents a 3.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mario Alberto Accardi also recently made the following trade(s):

• On Tuesday, September 16th, Mario Alberto Accardi sold 8,172 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $21.40, for a total value of $174,880.80.
• On Tuesday, September 9th, Mario Alberto Accardi sold 7,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $20.00, for a total value of $140,000.00.
• On Tuesday, July 29th, Mario Alberto Accardi sold 8,322 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.23, for a total value of $126,744.06.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA opened at $25.00 on Wednesday. The company has a market cap of $3.35 billion, a P/E ratio of -13.97 and a beta of 1.57. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.12 and a current ratio of 10.11. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $9.60 and a one year high of $25.31. The business’s 50-day simple moving average is $21.24 and its 200 day simple moving average is $16.49.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, sell-side analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CNTA has been the topic of several analyst reports. Lifesci Capital upgraded Centessa Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, September 3rd. Wells Fargo & Company began coverage on Centessa Pharmaceuticals in a research report on Wednesday, September 3rd. They set an “overweight” rating and a $31.00 price objective for the company. Truist Financial assumed coverage on Centessa Pharmaceuticals in a research report on Monday, July 21st. They set a “buy” rating and a $30.00 price objective for the company. Chardan Capital reiterated a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Finally, Stephens started coverage on Centessa Pharmaceuticals in a research report on Tuesday. They set an “overweight” rating and a $35.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.67.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of CNTA. Caitong International Asset Management Co. Ltd raised its position in Centessa Pharmaceuticals by 15,209.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock valued at $46,000 after buying an additional 3,194 shares during the period. Osterweis Capital Management Inc. acquired a new position in Centessa Pharmaceuticals in the 1st quarter worth about $47,000. Bank of New York Mellon Corp acquired a new position in shares of Centessa Pharmaceuticals during the 1st quarter valued at about $147,000. Fox Run Management L.L.C. acquired a new position in shares of Centessa Pharmaceuticals during the 1st quarter valued at about $160,000. Finally, Vestal Point Capital LP acquired a new position in shares of Centessa Pharmaceuticals during the 1st quarter valued at about $214,000. 82.01% of the stock is owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.